VRX - Valeant Pharmaceuticals International, Inc.

NYSE - NYSE Delayed price. Currency in USD
17.18
-0.15 (-0.87%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous close17.33
Open17.24
Bid0.00 x 0
Ask0.00 x 0
Day's range16.98 - 17.39
52-week range8.31 - 24.43
Volume4,933,810
Avg. volume10,555,536
Market cap5.993B
Beta-0.94
PE ratio (TTM)2.52
EPS (TTM)6.83
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date2010-11-10
1y target est17.03
Trade prices are not sourced from all markets
  • Implied Volatility Surging for Valeant (VRX) Stock Options
    Zacks3 days ago

    Implied Volatility Surging for Valeant (VRX) Stock Options

    Valeant (VRX) needs investors to pay close attention to the stock based on moves in the options market lately.

  • The Wall Street Journal9 days ago

    Paulson, Ackman and Sequoia: The Investors Who Took a Beating on Valeant

    Valeant Pharmaceuticals International Inc. keeps showing up next to the names of struggling investors.

  • Alexion to Acquire Wilson Therapeutics for $855 Million
    Market Realist9 days ago

    Alexion to Acquire Wilson Therapeutics for $855 Million

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.

  • Analyst Recommendations for Valeant Pharmaceuticals in April
    Market Realist12 days ago

    Analyst Recommendations for Valeant Pharmaceuticals in April

    According to the terms of the agreement, Kaken Pharmaceutical granted an exclusive license to Valeant Pharmaceuticals for the development and commercialization of products containing KP-470 for the treatment of dermatological and rheumatological disorders in the United States, Canada, Western Europe, and Eastern Europe. In January 2018, Valeant Pharmaceuticals’ subsidiary Bausch & Lomb announced that the European Commission granted a CE mark for the Stellaris Elite vision enhancement system. Nineteen analysts are tracking Valeant Pharmaceuticals in April 2018.

  • Valeant’s Xifaxan and Developments for Ortho-Dermatologics
    Market Realist12 days ago

    Valeant’s Xifaxan and Developments for Ortho-Dermatologics

    In 4Q17, Valeant Pharmaceuticals International’s (VRX) Xifaxan generated revenues of $275 million, compared to $251 million in 4Q16. That was a 10% growth on a YoY (year-over-year) basis and a 4% decline quarter-over-quarter.

  • Valeant Pharmaceuticals’ U.S. Diversified Top Products after 4Q17
    Market Realist12 days ago

    Valeant Pharmaceuticals’ U.S. Diversified Top Products after 4Q17

    In 4Q17, Valeant Pharmaceuticals International’s (VRX) Wellbutrin generated revenues of $67 million, a 10% growth on a quarter-over-quarter basis. In 4Q17, Wellbutrin’s YoY (year-over-year) growth was flat.

  • Teva Pharmaceutical’s Generic Medicines Segment in 2017
    Market Realist12 days ago

    Teva Pharmaceutical’s Generic Medicines Segment in 2017

    In fiscal 2017, Teva Pharmaceutical Industries’ (TEVA) generic medicines segment reported revenues of $12.3 billion compared to $12 billion in 2016, which was a 2% YoY (year-over-year) growth.

  • Valeant’s U.S. Diversified Products Segment in 4Q17 and 2017
    Market Realist13 days ago

    Valeant’s U.S. Diversified Products Segment in 4Q17 and 2017

    In 4Q17, Valeant Pharmaceuticals International’s (VRX) U.S Diversified Products generated revenues of $335 million compared to $398 million in 4Q16, a 16% decline on a YoY (year-over-year) basis.

  • Update on Bausch & Lomb’s Top Products since 4Q17
    Market Realist13 days ago

    Update on Bausch & Lomb’s Top Products since 4Q17

    In 4Q17, Soflens, a product of Valeant Pharmaceuticals International’s (VRX) subsidiary Bausch & Lomb, reported revenues of $78 million compared to $79 million in 4Q16. That was a 1% decline on a YoY (year-over-year) basis and a 6% decline quarter-over-quarter.

  • Valeant Pharmaceuticals’ Baush & Lomb in 4Q17 and 2017
    Market Realist13 days ago

    Valeant Pharmaceuticals’ Baush & Lomb in 4Q17 and 2017

    In 4Q17, Valeant Pharmaceuticals’ (VRX) subsidiary Bausch & Lomb reported revenues of $1.2 billion compared to $1.3 billion in 4Q16. That was a 3% growth on a YoY (year-over-year) basis and a 2% growth quarter-over-quarter.

  • Valeant Pharmaceuticals’ Branded Rx Products after 4Q17
    Market Realist16 days ago

    Valeant Pharmaceuticals’ Branded Rx Products after 4Q17

    Valeant Pharmaceuticals in 2017: An In-Depth Look at Its Performance

  • Valeant Pharmaceuticals’ Branded Rx Segment Performance in 4Q17
    Market Realist16 days ago

    Valeant Pharmaceuticals’ Branded Rx Segment Performance in 4Q17

    Valeant Pharmaceuticals in 2017: An In-Depth Look at Its Performance

  • Barrons.com16 days ago

    Valeant Pharmaceuticals: Getting Better?

    Valeant Pharmaceuticals (VRX) is bucking the market's slide on Friday, helped by an analyst upgrade. Mizuho's Irina Koffler boosted her rating on the stock to Neutral from Underperform, and raised her price target by $5, to $15. Koffler writes that the move comes as she sees an absence of near-term sell catalysts, and she believes that its can meet its 2018 guidance.

  • How Novartis’s Alcon Performed in 4Q17 and Fiscal 2017
    Market Realist20 days ago

    How Novartis’s Alcon Performed in 4Q17 and Fiscal 2017

    How Is Novartis Positioned after 4Q17?

  • Why Is Valeant (VRX) Up 4.3% Since Its Last Earnings Report?
    Zacks20 days ago

    Why Is Valeant (VRX) Up 4.3% Since Its Last Earnings Report?

    Valeant (VRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • 3 Sell-Rated Drug Stocks Investors Should Avoid for Now
    Zacks26 days ago

    3 Sell-Rated Drug Stocks Investors Should Avoid for Now

    Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.

  • Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead?
    Zackslast month

    Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead?

    Valeant's (VRX) stock has lost roughly 21% of its value in 2018 despite management's efforts for a turnaround after the turmoil in 2016.

  • Teva’s Recent Launch of Generic Solodyn: What You Need to Know
    Market Realistlast month

    Teva’s Recent Launch of Generic Solodyn: What You Need to Know

    Solodyn has an indication for the treatment of inflammatory lesions of moderate to severe acne in patients 12 years and older. The generic version of Solodyn is the ninth generic tetracycline-class drug in Teva’s portfolio. According to IMS data, Solodyn Extended Release 65 mg and 115 mg tablets generated sales of ~$148 million in the United States in 2017.

  • How the Market Reacted to Teva’s Pricing of Its Generic Syprine
    Market Realistlast month

    How the Market Reacted to Teva’s Pricing of Its Generic Syprine

    On February 9, 2018, Teva Pharmaceutical (TEVA) announced the US launch of its generic version of 250 mg Syprine capsules. Syprine capsules are trientine hydrochloride tablets, which are used for the treatment of penicillamine-intolerant patients suffering from Willson’s disease. Willson’s disease is a rare genetic disorder characterized by excessive copper in the body due to the body’s incapability to remove it, which can lead to life-threatening organ damage. According to the National Institute of Health, one in 30,000 people in the United States suffer from Willson’s disease.

  • MarketWatchlast month

    Valeant CEO compensation drops, was 138 times typical worker's pay in 2017

    Valeant Pharmaceuticals Inc. Chief Executive Joseph Papa received slightly less than $5 million in compensation in 2017, way down from the rewards he received when named to the position in 2016. Papa was ...

  • Are Options Traders Betting on a Big Move in Valeant (VRX) Stock?
    Zackslast month

    Are Options Traders Betting on a Big Move in Valeant (VRX) Stock?

    Investors need to pay close attention to Valeant (VRX) stock based on the movements in the options market lately.

  • Why Valeant Pharmaceuticals International Stock Sank in February
    Motley Foollast month

    Why Valeant Pharmaceuticals International Stock Sank in February

    Valeant's turnaround story hit a speed bump last month.

  • Barrons.comlast month

    Valeant: When Good News Goes Bad?

    Valeant Pharmaceuticals International (VRX) closed higher on Monday, helped by news of its $1.25 billion debt offering, maturing in 2026. Valeant has been on a wild ride lately, seeing its market value triple since bottoming in April 2016. Late last month the specialty-pharma giant lost ground after earnings, but it’s hard to ignore the balance sheet, as Valeant has been trying to shrink the large debt load it took on following an acquisition spree under previous management.

  • PDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y
    Zackslast month

    PDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y

    PDL BioPharma's (PDLI) earnings top estimates in Q4. Revenues also grow year over owing to rise in royalty rights.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes